MoonLake Immunotherapeutics Class A Ordinary Shares

MLTXNASDAQ • USD
11.25 USD
↘ 0.48 (4.09%)AT CLOSE (03:59 PM EST)
11.46
↗ 0.21 (1.88%)
POST MARKET (AS OF 07:56 PM EST)
Post Market
AS OF 07:56 PM EST
11.46
↗ 0.21 (1.88%)
🔴Market: CLOSED

MLTX is currently priced at $11.26. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 17, 2026.

Open?$11.72
High?$11.80
Low?$10.93
Prev. Close?$11.73
Volume?1.2M
Avg. Volume?1.7M
VWAP?$11.23
Rel. Volume?0.68x
Bid / Ask
Bid?$11.00 × 100
Ask?$11.98 × 300
Spread?$0.98
Midpoint?$11.49
Valuation & Ratios
Market Cap?998.3M
Shares Out?85.1M
Float?54.6M
Float %?64.2%
P/E Ratio?N/A
P/B Ratio?2.62
EPS?-$3.19
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Employees
130
Market Cap
998.3M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2022-04-06
Address
DORFSTRASSE 29
ZUG, V8 6300
Phone: 41 41 510 8022
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
18
Momentum?
50
Short Sent.?
56
Piotroski F-Score?0/9Weak
Altman Z-Score?1.39Distress
Confidence?58%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.03%High
Short Interest?5.5M
Days to Cover?2.9
Free Float54.6M
Avg Daily Volume1.9M
Settlement Date2026-10-30
Financial Health
Current Ratio?9.13Strong
Quick Ratio?9.13Strong
Cash Ratio?6.50Strong
Debt/Equity?0.26Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
62
2.62CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-71.0%WEAK▾
ROA?
S&P
3
-50.1%WEAK▾
Cash Flow & Enterprise
FCF?$-244041000
Enterprise Value?$718.6M
Fundamentals ratios updated end of day